Related Experiment Video
Updated: Aug 18, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
HIV resistance testing in the USA--a model for the application of pharmacogenomics in the clinical setting
Ronald A Blum1, Neil Wylie, Tom England
1Specialty Laboratories, 27027 Tourney Road, Valencia, CA 91355, USA. rblum@specialtylabs.com
Abstract:
Although there is debate about how and when the medical community will readily adopt pharmacogenomics into clinical practice, HIV genotyping has become an integral part of AIDS patient management in the USA since 1996. Genotyping for HIV-1 drug resistance serves as a paradigm for the way pharmacogenomics is likely to be introduced into patient care. This review discusses the unique role that HIV-1 genotype testing plays in identifying resistance in patients and how that information is used to modify therapy selection and impact the progression of disease. In addition, the important issues relating to reimbursement and the cost-effectiveness of genotyping are also discussed.
More Related Videos
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Therapeutic Drug Monitoring: Affecting Factors
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Therapeutic Drug Monitoring: Overview and Classification

